Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited evidence of their efficacy. Aficamten is a cardiac myosin inhibitor that ...
The hearts of people with hypertrophic cardiomyopathy are thicker, and must beat more forcefully to pump out blood into the body. This can lead to a variety of symptoms, which may appear only ...
MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...
Madrid, Spain – 30 August 2025: Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive ...
A global clinical trial involving The Hospital for Sick Children (SickKids) has found that mavacamten—a heart medication previously approved for adults—can safely and effectively improve the flow of ...
Cytokinetics, Incorporated announced findings from two analyses of the SEQUOIA-HCM trial that studied the effects of aficamten on patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM ...
Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to Cytokinetics conference call for the FDA approval of MYQORZO. [Operator ...
Dietary supplements cover a wide range of products, including vitamins, herbs, and minerals, many of which may be beneficial to your health. However, some supplements may not be safe if you are living ...
MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...
You can manage the risks of hypertrophic cardiomyopathy (HCM) with treatment and lifestyle changes. Here’s how to make the most of your next medical checkup. HCM is a genetic condition in which the ...
Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), ...
Please provide your email address to receive an email when new articles are posted on . Aficamten improved peak oxygen uptake at 24 weeks vs. metoprolol in patients with obstructive hypertrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results